Pfizer's late-stage BRAF V600E-mutant mCRC study of the Braftovi combo regimen meets its other dual primary endpoint of PFS ...

The combination of Opdivo and Yervoy is supported by updated results as a standard of care for MSI-H or dMMR metastatic ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

Pfizer’s metastatic colorectal cancer (mCRC) combination therapy has met one of the primary endpoints of improving ...

For patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), encorafenib + cetuximab (EC) plus standard chemotherapy (modified folinic acid [or levofolinate], fluorouracil, and oxaliplatin ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

Pfizer only picked up an accelerated approval from the FDA for its Braftovi-based combination regimen for colorectal cancer ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

World Cancer Day also marks the start of the ‘United by Unique’ campaign, which seeks to highlight how each person’s journey ...

Kayla Jones: "I never thought I'd need an organ. Never in my wildest dreams did I think I would need an organ at 35." ...

Pfizer has announced that its Braftovi (encorafenib) regimen significantly improved both progression-free and overall ...

The National Comprehensive Cancer Network joins a global day of advocacy to put people's individual needs and stories at the ...